androgens + anabolics

androgens are not peptides. this page compares the depth and limits of their evidence, not what a person should take.

this class cannot be ranked by folklore potency ratios or one borrowed half-life. ester, route, oil vehicle, suspension, oral design, population, and endpoint change the record. testosterone is the clinical reference; oxandrolone, oxymetholone, and nandrolone have substantial but indication-specific human files; several others rely on old, foreign, veterinary, or animal evidence.

no randomized human body-composition head-to-head of two androgen compounds was located. every comparison here is therefore a cross-trial evidence map, not head-to-head proof. S-tier means a deeper documented record. it does not mean low risk, current availability, or suitability for nonmedical use.

human evidence exists, with formulation and indication attached.

the strongest files in this lane also contain direct hepatic, lipid, endocrine, reproductive, hematologic, and cardiovascular warnings.

testosterone (tier S) — the clinically characterized reference androgen with approved products, extensive human PK, and a large safety literature.
oxandrolone (anavar) (tier S) — oral 17-alpha-alkylated androgen with measured human PK and controlled burn outcomes; US approvals withdrawn in 2023.
oxymetholone (anadrol) (tier S) — oral anemia drug with controlled human anabolic outcomes and severe dose-related hepatic and lipid harm.
nandrolone (tier A) — 19-nor androgen with formulation-specific human PK and a current Australian nandrolone decanoate authorization.

a name in medicine or animal practice is not a modern human safety file.

these records range from small historical oncology series to current foreign labels, veterinary depot PK, and research-chemical evidence. none may borrow another androgen's half-life or safety margin.

drostanolone (masteron) (tier B) — historical dromostanolone propionate oncology drug with small human series and no validated systemic half-life.
methenolone (primobolan) (tier B) — current Japanese oral acetate medicine with historical injectable enanthate use and no validated systemic half-life for either form.
methandienone (dianabol) (tier B) — oral 17-alpha-methyl androgen with an old controlled weightlifter trial and US withdrawals for lack of substantial efficacy evidence.
stanozolol (winstrol) (tier B) — 17-alpha-alkylated androgen whose controlled human evidence includes large adverse lipid changes.
trenbolone (tier F) — current cattle androgen with historical French human marketing and no modern controlled human therapeutic PK or safety program.
boldenone (equipoise) (tier F) — veterinary horse drug with equine undecylenate depot PK and no controlled human therapeutic program.
yk-11 (tier F) — steroidal androgen-receptor research chemical with cell and animal studies but no controlled human trial or measured half-life.

what the evidence can and cannot compare.

which androgen is best for body composition?

the literature does not support that ranking. populations, outcomes, formulations, and study eras differ, and no randomized human body-composition head-to-head of two androgen compounds was located. cross-trial outcomes are not head-to-head evidence. the board grades documentation depth, not personal benefit.

can one androgen's half-life be used for another?

no. free parent, ester, oil vehicle, injection site, depot volume, aqueous suspension, oral formulation, and species all matter. nandrolone decanoate has human depot PK; boldenone and stanozolol values in this dossier are animal and formulation specific; several compounds have no qualifying systemic half-life at all.

does S-tier mean an androgen is safer?

no. S-tier means a deeper, more auditable evidence record. oxandrolone and oxymetholone grade S because they have substantial human and regulatory files, and those same files document severe hepatic and lipid risks. evidence depth can make harm clearer.

which records are current human approvals?

testosterone has current approved products. nandrolone decanoate has a current Australian authorization, and methenolone acetate has a current Japanese label. oxymetholone's US NDA remains legally approved but listed products are discontinued. oxandrolone approvals were withdrawn in 2023. other entries have historical, veterinary, or unapproved status that must be read individually.

is YK-11 just another oral steroid?

it is a steroidal androgen-receptor research chemical, but the usual shortcuts fail. it is not a peptide, not a conventional DHT derivative, and not established as a 17-alpha-alkylated oral androgen. those structural corrections do not supply human efficacy, PK, or safety evidence.

shared class risks, formulation-specific evidence.

what risks recur across androgen records?

hypothalamic-pituitary-gonadal suppression, impaired spermatogenesis and fertility, virilization, erythrocytosis or hematologic change, edema, adverse lipid effects, blood-pressure and cardiovascular concern, and product-specific hepatic risk recur across the class. the magnitude and directness of evidence differ by compound and formulation.

why do the oral 17-alpha-alkylated compounds get separate warnings?

oxandrolone, methandienone, stanozolol, and oxymetholone carry oral designs associated with cholestatic injury and adverse lipid handling. injection does not rescue stanozolol because its injectable form is the same unesterified 17-alpha-alkylated molecule in aqueous suspension.

are injectable androgens liver-safe?

no blanket claim is supported. avoiding a 17-alpha-alkylated oral design changes one risk pathway, not the entire safety profile. endocrine suppression, fertility, virilization, hematologic, edema, cardiovascular, excipient, sterility, concentration, and product-identity risks remain.

what changes when the product is veterinary or underground?

a molecule's animal-drug authorization does not establish human formulation quality or use. concentration, ester identity, oil or suspension vehicle, sterility, endotoxin, particulates, and impurities become separate exposure risks on top of the pharmacology.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.